Posted byOrthoEx Posted in,
Posted on Oct 04, 2018

October 04, 2018

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:

Implanet (Paris:ALIMP) (OTCQX:IMPZY) (Euronext Growth: ALIMP, FR0010458729, eligible for PEA-PME equity savings plans; OTCQX: IMPZY), a medical technology company specializing in vertebral and knee surgery implants, announces the completion of its first surgery in the United Kingdom via Implanet UK, at the Royal Orthopaedic Hospital of Birmingham, following the opening of its branch in early June1.

The recent listing of Implanet UK and its Jazz® platform on the NHS (National Health Service), the United Kingdom’s public health system providing the bulk of care, particularly in hospitals, allows Implanet UK to offer Jazz® to all public hospitals in the country.

As a reminder, the United Kingdom is the second largest market in Europe for spinal fusion back surgery. The potential in adult degenerative spine disease is estimated at over $100 million2.

Next press release: 3rd quarter 2018 revenue on October 9, 2018 before the market opens.


Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ® latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 46 staff and recorded 2017 sales of €7.8 million. For further information, please visit Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013. IMPLANET is listed on Euronext™ Growth market in Paris. The Company would like to remind that the table for monitoring the BEOCABSA, OCA, BSA and the number of shares outstanding, is available on its website:

1 IMPLANET announces opening of a United Kingdom sales branch
2 Mordor Intelligence 2017 study


Ludovic Lastennet, +33 (0)5 57 99 55 55
Investor Relations
Julie Coulot, +33 (0)1 44 71 20 40
Media Relations
Nicolas Merigeau, +33 (0)1 44 71 94 98
US-Investor Relations
Pascal Nigen, +1-917-385-21 60